GleamWall
中文EN

ISPC iSpecimen Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.0%
TTM net income YoY5.9%
TTM EPS YoY180.8%
Revenue 3-yr CAGR-61.2%
Net income 3-yr CAGR—

Margins

Gross margin-10.3%
Operating margin-1,455.3%
Net margin-1,797.3%
FCF margin—
EBITDA margin-1,364.6%

Returns

ROE-303.9%
ROA-116.1%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets58.1%
Debt / equity0.00x
Current ratio1.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$244,034$151,940$156,009$51,761$106,592$713,135$1.06M$1.48M
Cost of revenue$91,156$83,290$84,410$407,284$204,593$444,177$657,279$1.28M
Gross profit$152,878$68,650$71,599-$355,523-$98,001$268,958$400,231$199,241
SG&A expense$547,984$442,508$680,415$901,130$864,061$948,376$758,666$2.02M
Operating income-$2.20M-$1.36M-$2.54M-$2.69M-$2.83M-$1.82M-$1.64M-$5.84M
Interest expense$27,500——$1$2$0$1,946$157,468
Net income-$2.21M-$1.36M-$2.28M-$5.00M-$2.78M-$1.05M-$1.66M-$6.05M
EBITDA-$2.20M-$1.36M-$2.40M-$2.28M-$2.81M-$1.80M-$1.21M-$5.29M
EPS (basic)-1.03-0.98-6.66—-19.05-16.78-28.55—
EPS (diluted)-1.03-0.98-6.66—-19.05-16.78-28.55—
Weighted avg. shares (diluted)2.16M1.39M341,377—145,99662,42458,078—
Balance sheet
Cash & equivalents$5.56M$4.41M$2.82M$6.88M$2.78M$588,775$782,563$1.88M
Receivables$50,448$21,257$132,848$48,298$120,931$372,469$581,652$1.44M
Inventory———————$45,110
Current assets$6.34M$4.48M$3.48M$6.95M$3.60M$1.17M$1.53M$3.59M
PP&E, net$19,798$21,011$23,134$25,543$42,666$59,789$76,460$93,563
Total assets$9.70M$7.39M$6.61M$9.53M$9.00M$6.03M$6.84M$9.35M
Current liabilities$5.47M$5.48M$5.60M$6.23M$5.70M$5.17M$4.92M$5.77M
Total liabilities$5.63M$5.66M$5.80M$6.44M$5.92M$5.41M$5.17M$6.04M
Shareholders' equity$4.07M$1.74M$814,038$3.09M$3.07M$621,973$1.67M$3.31M
Shares outstanding2.76M1.52M741,556211,9769.77M2.50M2.50M1.70M
Cash flow statement
Operating cash flow-$2.70M-$689,625-$3.36M-$916,923-$2.04M-$192,234-$1.10M-$3.57M
Capital expenditure———$0$0——$7,865
Free cash flow———-$916,923-$2.04M——-$3.58M
Investing cash flow-$700,941$0-$700,000$0-$1.00M——-$73,060
Financing cash flow$4.54M——$5.01M$5.23M——$3.77M
Depreciation & amortization$2,154$2,123$135,945$407,731$17,123$17,125$432,709$548,036
Stock-based compensation$153$153$1,028$1,765$1,797$1,803$15,901$10,972

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.